Adalimumab Biosimilar on Par With Original in Crohn's Disease Adalimumab Biosimilar on Par With Original in Crohn's Disease

For patients with moderate to severe active Crohn's disease, the adalimumab biosimilar BI 695501 from Boehringer Ingelheim proved as safe and effective as the original, AbbVie's Humira, in the phase-3 VOLTAIRE-CD study.Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Related Links:

CROHN'S disease is the painful digestive condition with unusual warning signs. The colour of your poo being one of them. What to look out for?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
In this study, we described a unique case of cutaneous metaplasia on the elbow of a 25-year-old man who had a clinical history of epidermolysis bullosa simplex, but had no history of any gastrointestinal disease. The lesion had been clinically stable for 5 years. Histopathologically, the epithelium showed many columnar cells with mucinous cytoplasm, with no atypia or mitoses. The proliferation rate was low (7% by Ki67). The metaplastic areas expressed epithelial membrane antigen, carcinoembryonic antigen, cytokeratin 7, MUC5AC, MUC2, and Cyclin-D1.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Locum - Physician - Gastroenterologist Pittsfield, MA This will be an ongoing assignment Patient Volume: 5-10 consults per day, 5-10 procedures per day (during the week). A few patients and occasional procedures on weekends. Travel/lodging is reimbursable We provide treatment for all digestive diseases and conditions including: • Digestive tract bleeding • Celiac disease • Colitis • Colon polyps • Crohns • Incontinence • Gallstones • Hemochromatosis • Hepatitis • Irritable Bowel... Read more
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Gastroenterology Source Type: forums
Crohn's disease (CD) patients included in the TAILORIX trial started infliximab in combination with an immunosuppressant for one year. The aim of the present study was to determine the long-term disease course beyond the study period.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
CONCLUSION: The rate of MEFV gene mutations was high in patients with UC who required surgery. These patients have frequent and severe attacks, indicating that the mutations are related to disease severity. MEFV mutation as a modifier factor of IBD should be considered.PMID:34819953 | PMC:PMC8608532 | DOI:10.1155/2021/5538150
Source: Gastroenterology Research and Practice - Category: Gastroenterology Authors: Source Type: research
Z Gastroenterol. 2021 Nov 24. doi: 10.1055/a-1672-4861. Online ahead of print.ABSTRACTInflammatory bowel diseases have recorded increasing incidence. A long period of illness and immunsuppressive drugs run a high risk of complications, this is particularly true for neoplasias.Medical records of patients with inflammatory bowel diseases who developed a malignant disease during 2000 and 2020 were used for analysis.51 patients could be included. 56% of tumors were located extraintestinal and occurred more often in patient with Crohn's disease. Neoplasias were more frequent in men (61 %).Individual prevention recommendations a...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Source Type: research
Rev Esp Enferm Dig. 2021 Nov 25. doi: 10.17235/reed.2021.8457/2021. Online ahead of print.ABSTRACTCrohn's disease of the reservoir is a pathology of difficult diagnosis and complex approach due to the scarce documented evidence on it. Recently, studies have been published on the treatment strategies available for this entity. Based on the above, we have analyzed the experience of our center in the treatment of reservoir Crohn's disease with one of the new biologic agents, ustekinumab.PMID:34818897 | DOI:10.17235/reed.2021.8457/2021
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Authors: Source Type: research
Z Gastroenterol. 2021 Nov 24. doi: 10.1055/a-1672-4861. Online ahead of print.ABSTRACTInflammatory bowel diseases have recorded increasing incidence. A long period of illness and immunsuppressive drugs run a high risk of complications, this is particularly true for neoplasias.Medical records of patients with inflammatory bowel diseases who developed a malignant disease during 2000 and 2020 were used for analysis.51 patients could be included. 56% of tumors were located extraintestinal and occurred more often in patient with Crohn's disease. Neoplasias were more frequent in men (61 %).Individual prevention recommendations a...
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Source Type: research
CONCLUSION: The rate of MEFV gene mutations was high in patients with UC who required surgery. These patients have frequent and severe attacks, indicating that the mutations are related to disease severity. MEFV mutation as a modifier factor of IBD should be considered.PMID:34819953 | PMC:PMC8608532 | DOI:10.1155/2021/5538150
Source: Gastroenterology Research and Practice - Category: Gastroenterology Authors: Source Type: research
Rev Esp Enferm Dig. 2021 Nov 25. doi: 10.17235/reed.2021.8457/2021. Online ahead of print.ABSTRACTCrohn's disease of the reservoir is a pathology of difficult diagnosis and complex approach due to the scarce documented evidence on it. Recently, studies have been published on the treatment strategies available for this entity. Based on the above, we have analyzed the experience of our center in the treatment of reservoir Crohn's disease with one of the new biologic agents, ustekinumab.PMID:34818897 | DOI:10.17235/reed.2021.8457/2021
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Authors: Source Type: research
More News: Crohn's Disease | Gastroenterology | Humira | Inflammatory Bowel Disease | Study